The effect of cannabinoid receptor agonist WIN 55,212-2 on anxiety-like behavior and locomotion in a genetic model of absence seizures in the elevated plus-maze.
Journal
CNS neuroscience & therapeutics
ISSN: 1755-5949
Titre abrégé: CNS Neurosci Ther
Pays: England
ID NLM: 101473265
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
revised:
04
04
2022
received:
08
03
2022
accepted:
07
04
2022
pubmed:
27
4
2022
medline:
8
7
2022
entrez:
26
4
2022
Statut:
ppublish
Résumé
GAERS and NEC rats were treated with cannabinoid 1/2 receptor agonist WIN 55,212-2 2 mg/kg and tested on the Elevated Plus-Maze.
Identifiants
pubmed: 35470960
doi: 10.1111/cns.13848
pmc: PMC9253729
doi:
Substances chimiques
Benzoxazines
0
Cannabinoid Receptor Agonists
0
Morpholines
0
Naphthalenes
0
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone
5H31GI9502
Types de publication
Letter
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1268-1270Informations de copyright
© 2022 The Authors. CNS Neuroscience & Therapeutics Published by John Wiley & Sons Ltd.
Références
Epilepsy Behav. 2020 Jan;102:106722
pubmed: 31855784
Epilepsia. 2014 Sep;55(9):1460-8
pubmed: 25059093
Neuropharmacology. 2021 Jun 1;190:108553
pubmed: 33845076
Epilepsia. 2021 May;62(5):1041-1056
pubmed: 33751566
Epilepsia. 2010 Aug;51(8):1511-21
pubmed: 20132294
Neuropharmacology. 2016 Sep;108:292-304
pubmed: 27085605
Epilepsy Res. 1991 Jul;9(2):97-104
pubmed: 1794357
Brain. 2020 Aug 1;143(8):2341-2368
pubmed: 32437558
Eur J Neurosci. 2016 Jan;43(1):25-40
pubmed: 26490879
Neurobiol Dis. 2010 Jul;39(1):116-25
pubmed: 20153428
Eur J Pharmacol. 2007 Jun 1;563(1-3):141-8
pubmed: 17374533
Prog Brain Res. 2021;259:83-134
pubmed: 33541682